Cohance Lifesciences Limited (NSEI: COHANCE)
Health Care · Pharmaceuticals · IN
Rs463.00
+5.07% today · -48.5% 1Y
Cohance Lifesciences Limited (NSEI: COHANCE) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $1.85B and employs 1,193 people.
Over the last twelve months the share price has lost 48.5%, trading between 266.70 and 1.04K.
Tweenvest scores Cohance Lifesciences Limited across four factors: quality 69/100, value 47/100, growth 26/100. Its strongest factor is quality.
COHANCE price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $1.85B
- Revenue (TTM)
- $226.49M
- P/E
- —
- EPS
- —
- Dividend yield
- —
- Beta (5Y)
- 0.60
- 52-week high
- Rs1,038.90
- 52-week low
- Rs266.70
- Avg volume (3M)
- —
- Shares outstanding
- 382.57M
- Employees
- 1,193
- Next earnings
- —
About Cohance Lifesciences Limited
Headquartered in Hyderabad, Cohance Lifesciences Limited operates as a pharmaceutical enterprise, with primary expertise in contract development and manufacturing (CDMO) services. Its business scope also includes the creation of active pharmaceutical ingredients (APIs) and diverse specialty chemicals. The company, previously known as Suven Pharmaceuticals Limited, underwent a corporate rebranding following its amalgamation with Cohance Lifesciences, a transition officially effective May 1, 2025.
- ISIN
- INE03QK01018
- Founded
- 1989
- Listed since
- Mar 9, 2020
- Exchange
- National Stock Exchange of India
- Currency
- INR
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Eli Lilly and CompanyNYSE: LLY | $1.12T | $1,255.40 | +0.88% |
| Johnson & JohnsonNYSE: JNJ | $651.25B | $270.24 | +1.07% |
| Merck & Co., Inc.NYSE: MRK | $376.37B | $152.55 | +2.39% |
| Roche Holding AGSWX: ROP | $373.91B | CHF375.60 | +1.02% |
| Novartis AGSWX: NOVN | $302.17B | CHF127.42 | +0.85% |
| AstraZeneca PLCLSE: AZN | $258.76B | £122.40 | +1.26% |
| Novo Nordisk A/SCPSE: NOVO B | $207.84B | Dkr300.85 | +1.59% |
| Pfizer Inc.NYSE: PFE | $159.99B | $28.07 | +1.01% |
Figures last refreshed Aug 18, 2026.